“ While current discussions often focus on economic incentives, the present onshoring momentum is best understood as an extension of what began during COVID... ”
In Conversation
“ The field is in a pivotal moment. We are seeing remarkable scientific progress, from personalised gene editing and in vivo delivery to an expanding pipeline addressing… ”
“ In the ultra-rare space, one size does not fit all. Every disease state has unique nuances, ranging from diagnostics to distribution and market access ”
“ We are about to enter a new era of cancer treatment, made possible by technologies that will modernise clinical research in ways that we have not… ”
“ Behind every test is a real patient who is seeking answers ”
“ Resources are finite, and the goal is not to pursue every idea, but to focus on those with the greatest potential to address unmet needs ”
“ We focus on medicines that larger companies may overlook, where the real-world disease burden and patient need are not fully appreciated ”
“ Diagnostics are no longer peripheral. They are central to delivering the full value of precision medicine ”
“ Regulatory conclusions reached in the past should never be assumed to apply indefinitely ”
“ Ultimately, success in rare disease launches comes down to flexibility and adaptability ”
“ The largest disconnect between approval and patient access is that much of the healthcare system is structurally designed to say “no.” ”
“ Sustaining innovation requires consistent investment in top scientific talent. When funding is this constrained, risk-taking and long-term discovery inevitably suffer ”
